Pharmaceutical HIV/AIDS specialist firm ViiV Healthcare, which is majority owned by GlaxoSmithKline, today announced that it will be developing the investigational broadly neutralizing antibody (bNAb) N6LS for the treatment and prevention of HIV-1, as part of an exclusive licensing agreement between GSK and the National Institute of Allergy and Infectious Diseases (NIAID), part of the USA’s National Institutes of Health (NIH). 21 November 2019